Early preclinical evidence demonstrated that activation of the programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) axis suppressed the activation and proliferation of tumor antigen-specific T-cells and promoted tumorigenesis [1, 2]. Here, PDCD1 is linked to neoplasm.